Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain activ... Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. 詳細を表示
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1105 | -17.8082191781 | 0.6205 | 0.63 | 0.49 | 56962 | 0.53891193 | CS |
4 | -0.1737 | -25.4058797718 | 0.6837 | 0.8 | 0.49 | 48081 | 0.63544149 | CS |
12 | -0.1912 | -27.2675413577 | 0.7012 | 1.1099 | 0.49 | 248519 | 0.86688822 | CS |
26 | -0.85 | -62.5 | 1.36 | 1.87 | 0.49 | 124719 | 0.89679042 | CS |
52 | -0.34 | -40 | 0.85 | 1.87 | 0.49 | 67131 | 0.90991756 | CS |
156 | -7.49 | -93.625 | 8 | 9.4 | 0.49 | 62001 | 3.7324131 | CS |
260 | -14.45 | -96.5909090909 | 14.96 | 19.56 | 0.49 | 347489 | 10.81110455 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約